- Breast cancer in very young (aged ≤35 years) vs young (aged 36-45 years) patients is biologically more aggressive and tied to poorer survival.
Why this matters
- Very young patients merit their own subgroup for clinical trials and further research.
- Retrospective cohort with breast cancer (n=598) of the National Institute of Oncology, Hungary (2000-2014).
- 297 patients were very young; 301 patients were young.
- Funding: None disclosed.
- Median follow-up for very young patients was 69 months; that for young women was 79 months.
- The very young vs young patients were more likely to:
- have triple-negative breast cancer (31% vs 16.9%; P=.00008),
- have estrogen receptor-negative cancer (8.4% vs 7.3%; P=.00008),
- have distant metastasis at diagnosis (3% vs 0.3%; P=.01), and
- receive chemotherapy (73.5% vs 66.7%; P=.049).
- Very young vs young patients were less likely to receive endocrine therapy (57% vs 65.7%; P=.037).
- No differences between groups in rates of radiotherapy, breast-conserving surgery, or mastectomy.
- Very young patients had worse DFS (P=.00004) and OS (P=.00005) than young patients.
- Lack of information on behavioral risk factors.
- Low rate of BRCA testing.
- Not clear whether cohort is multicenter or single center.